Get the Stockscreener App
6.30
3.23%
-0.21
After Hours:
6.30
Sight Sciences Inc stock is traded at $6.30, with a volume of 164.86K.
It is down -3.23% in the last 24 hours and down -6.94% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
See More
Previous Close:
$6.51
Open:
$6.51
24h Volume:
164.86K
Relative Volume:
0.80
Market Cap:
$313.92M
Revenue:
$81.06M
Net Income/Loss:
$-55.55M
P/E Ratio:
-4.3151
EPS:
-1.46
Net Cash Flow:
$-47.98M
1W Performance:
-3.96%
1M Performance:
-6.94%
6M Performance:
+19.32%
1Y Performance:
+86.94%
1-Day Range:
$6.14
$6.54
1-Week Range:
$6.14
$6.82
52-Week Range:
$1.04
$8.45
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Institutional investors own a significant stake of 34% in Sight Sciences, Inc. (NASDAQ:SGHT) - Yahoo Finance
Long Focus Capital Management LLC Increases Stake in Sight Sciences, Inc. (NASDAQ:SGHT) - MarketBeat
Sight Sciences gains Medicare coverage for eye surgery tech By Investing.com - Investing.com Canada
Sight Sciences gains Medicare coverage for eye surgery tech - Investing.com India
Sight Sciences gains Medicare coverage for eye surgery tech - Investing.com
Where did Mars' atmosphere go? Scientists say it may be 'hiding in plain sight' - Space.com
(SGHT) Investment Report - Stock Traders Daily
Vitreoretinal Surgery Devices Market Advancements Highlighted by Demand, Growth Prediction, Segments And Ou... - WhaTech
GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates - sharewise
Stock Traders Buy Large Volume of Summit Therapeutics Call Options (NASDAQ:SMMT) - MarketBeat
Angel Studios’ Inspirational Movie SIGHT Now Available for Digital Download - Movieguide
Seeing Machines remains overlooked by market despite major advances - MSN
SMALL CAP IDEA: Seeing Machines remains overlooked by market - This is Money
Bank of New York Mellon Corp Increases Holdings in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
SPACETALK Stakeholder Sells and Dilutes Shares - TipRanks
(SEM) Long Term Investment Analysis - Stock Traders Daily
Select Medical Holdings Co. (NYSE:SEM) Shares Acquired by Dimensional Fund Advisors LP - Defense World
A Clearer View: Global Glaucoma Surgery Devices Market Report 2024 - WhaTech
Examining the Potential Price Growth of Surgery Partners Inc (SGRY) - Knox Daily
Smart Money Is Betting Big In SMMT Options - Benzinga
This company generates no revenue and its market cap is over $20 billion. Here's why that valuation - The Bharat Express News
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous. - The Motley Fool
Why the Fed's soft landing is in sight: Opening Bid - Yahoo Finance
APA’s (APA) “Sector Perform” Rating Reaffirmed at Royal Bank of Canada - Defense World
Starwood Property Trust’s $391.7 Million Common Stock Offering - Global Legal Chronicle
Breakthrough Discovery in the Cause of Congenital Nystagmus - EIN News
Here's Why Everyone's Talking About Summit Therapeutics - sharewise
This is why everyone is talking about Summit TherapeuticsTHE BHARAT EXPRESS NEWS - The Bharat Express News
Here's Why Everyone's Talking About Summit Therapeutics - AOL
Summit Therapeutics (NASDAQ:SMMT) Sets New 52-Week High Following Analyst Upgrade - Defense World
Summit Therapeutics stock soars to all-time high of $33.62 - Investing.com India
Summit Therapeutics (NASDAQ:SMMT) PT Raised to $45.00 - MarketBeat
Summit Therapeutics shares target by H.C. Wainwright raised on positive data - Investing.com
How To Trade (SGHT) - Stock Traders Daily
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda - MSN
Why Summit Therapeutics Surged 123% This WeekTHE BHARAT EXPRESS NEWS - The Bharat Express News
Why Summit Therapeutics Skyrocketed 123% This Week - The Motley Fool
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - The Malaysian Reserve
Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says - The Conversation
Summit Therapeutics jumps 4%, raises $235M - MSN
Brokerages Set Sight Sciences, Inc. (NASDAQ:SGHT) Price Target at $6.42 - MarketBeat
A company insider recently sold 5,055 shares of Sight Sciences Inc [SGHT]. Should You Sale? - Knox Daily
Perhaps timely catching Sight Sciences Inc (SGHT) would be a good idea - SETE News
Panagora Asset Management Inc. Lowers Position in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Lake Street Initiates Coverage of Sight Sciences (SGHT) with Buy Recommendation - Nasdaq
Sight Sciences (NASDAQ:SGHT) Coverage Initiated at Lake Street Capital - MarketBeat
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference - GlobeNewswire
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference - StockTitan
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference - Yahoo Finance
How to Take Advantage of moves in (SGHT) - Stock Traders Daily
Vanguard Group Inc. Purchases 81,768 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):